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Abstract
Background: After development of hormone-refractory metastatic disease, prostate cancer is
incurable. The recent history of chemotherapy has shown that with difficult disease targets,
combinatorial therapy frequently offers the best chance of a cure. In this study we have examined
the effects of a combination of zoledronic acid (ZOL), a new-generation bisphosphonate, and
docetaxel on LuCaP 23.1, a prostate cancer xenograft that stimulates the osteoblastic reaction
when grown in the bone environment.
Methods: Intra-tibial injections of LuCaP 23.1 cells were used to generate tumors in the bone
environment, and animals were treated with ZOL, docetaxel, or a combination of these. Effects on
bone and tumor were evaluated by measurements of bone mineral density and
histomorphometrical analysis.
Results: ZOL decreased proliferation of LuCaP 23.1 in the bone environment, while docetaxel at
a dose that effectively inhibited growth of subcutaneous tumors did not show any effects in the
bone environment. The combination of the drugs significantly inhibited the growth of LuCaP 23.1
tumors in the bone.
Conclusion: In conclusion, the use of the osteolysis-inhibitory agent ZOL in combination with
docetaxel inhibits growth of prostate tumors in bone and represents a potential treatment option.
Background
Patients with advanced prostate cancer (CaP) suffer from
the severe consequences of hormone-refractory disease
and bone metastases. After development of metastatic
hormone-refractory disease, CaP is incurable, with a
median survival of 9 to 12 months. Given the near-cer-
tainty that processes associated with hormone-refractory
CaP and bone metastasis contribute directly to morbidity
(pain, bone fractures, bone marrow failure) of patients,
treatment modalities that would eliminate the advanced
disease, slow down progression, or improve the quality of
life of patients with advanced CaP are of great interest.
Hormonal therapy, radiotherapy, and chemotherapy do
not cure hormone-refractory disease [1]. Attacking the
tumor cells by multiple mechanisms may prove to be
much more effective in killing tumor cells; therefore com-
bined chemotherapies are one of the most promising
themes of today's clinical picture.
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Zoledronic acid (ZOL) is one of the most potent of the
new-generation bisphosphonates (BPs), compounds that
inhibit bone lysis and have been used in the treatment of
bone diseases and bone metastastatic disease [2-7], and
stimulate apoptosis in cancer cells [8-10]. Effects of ZOL
on tumor cells [11,12], including prostate tumors [13-19],
have been reported in the literature. In our previous in vivo
studies we have shown that growth of subcutaneous CaP
tumors was not inhibited by ZOL; however, growth of
prostate cancer cells in the bone environment was signifi-
cantly inhibited, but the tumors were not eradicated [15].
We have also shown that the probable mechanisms of the
effects of ZOL on tumor in bone are indirect, via its effects
on bone cells [19]. The value and potential of ZOL in
treatment of patients with cancer-related bone disease
were reviewed [5], and a large number of reports have
recently documented the benefits of ZOL treatment in
patients with advanced prostate cancer [20-31]. However,
in parallel with our pre-clinical study, these published
results suggest that BPs can slow progression of the dis-
ease, but a cure is not achieved. Therefore, combinations
of BPs with other agents such as chemotherapeutic drugs
to control tumor growth while regulating tumor-induced
bone remodeling have appeared as a promising new treat-
ment strategy.
Docetaxel, an inhibitor of tubulin depolymerization, has
emerged as the most valuable chemotherapeutic treat-
ment for advanced CaP. Phase II studies have shown
decreased prostate specific antigen (PSA) levels and
increased survival, with dosage amounts and regimens
varying from 25–75 mg/m2 every 1 or 3 weeks [32-37].
However, the toxicity of this treatment is significant and
complete cures are still not achieved [34].
The recent history of chemotherapy has shown that with
difficult disease targets, combinatorial therapy frequently
offers the best chance of a cure. Therefore testing of com-
binations of BPs with other agents is of significant interest
in the treatment of various cancers. Many of the initial
studies of BPs in combination with chemotherapy were
conducted on breast cancer or myeloma, where the bone
lesions are highly osteolytic. Combinations of taxoids
with BPs in vitro exhibited additive anti-tumor effects
against invasion and adhesion [38] and induction of
apoptosis in breast-cancer cells in vitro [39] and in vivo
[40]. Moreover, inclusion of BPs in standard chemother-
apy has led to a sustained reduction in skeletal complica-
tions in breast-cancer patients [41-43]. In advanced CaP
patients, ZOL in combination with docetaxel and low-
dose estramustine phosphate was recently shown to
decrease serum PSA and pain levels [34]. Additionally,
Vordos  et al. reported that ZOL in combination with
docetaxel decreased serum PSA by over 50% at 2 months
in more than half of the patients [25]. It has also been
reported that the alendronate in combination with taxol
is more effective in preventing development of bone
metastases in a CaP animal model than either therapy
independently [44].
In this study we used a combination of ZOL and docetaxel
to evaluate changes in bone remodeling and tumor
growth of an osteoblastic CaP xenograft, LuCaP 23.1.
Methods
Xenograft
All procedures were performed in compliance with the
University of Washington Institutional Animal Care and
Use Committee and NIH guidelines. LuCaP 23.1 is a PSA-
producing human CaP xenograft [45], which is main-
tained subcutaneously (SC) in male athymic mice.
Intra-tibial tumors and docetaxel and zoledronic acid 
treatment
The right tibiae of forty male SCID mice (four-to-six-week-
old, Fox Chase SCID mice, Charles River, Wilmington,
MA) were injected with 2 × 105 LuCaP 23.1 cells as we
have described previously [15]. Briefly, 1–2 × 105 sepa-
rated single LuCaP 23.1 cells in ~10–20 µl were injected
into the proximal end of the tibia. After the procedures,
animals received Buprenorphine as an analgesic (2 mg/kg
body weight subcutaneously) until fully recovered (usu-
ally <24 hours). The tumor growth was monitored by
measurements of serum prostate specific antigen (PSA)
levels. The animals were randomized into 4 groups when
tumors in bone were established (mean serum levels of
PSA: 5–10 ng/ml). Groups were as follows: 1) a control
group which received subcutaneous PBS injections; 2) a
ZOL treatment group which received subcutaneous injec-
tions of ZOL twice a week (2.5 µg per injection, ~0.1 mg/
kg, Novartis Pharma AG, Basel, Switzerland.); 3) a
docetaxel treatment group which received intra-peritoneal
injections of docetaxel every two weeks (400 µg per injec-
tion, 20 mg/kg, Aventis Pharmaceuticals Inc. Bridgewater,
NJ); and 4) a group treated with a combination of ZOL +
docetaxel which received subcutaneous injections of ZOL
twice a week (2.5 µg per injection, ~0.1 mg/kg) and intra-
peritoneal injections of docetaxel every two weeks (400 µg
per injection, 20 mg/kg). Docetaxel was dissolved in eth-
anol and polysorbate 80. The final dilutions were pre-
pared just before injection with 5% dextrose. Blood
samples were collected every week for determination of
serum PSA levels (IMx Total PSA assay, Abbott Laborato-
ries, Abbott Park, IL). The mice were sacrificed 7 weeks
after enrolment. Bone mineral density (BMD) was meas-
ured prior to sacrifice in the area adjacent to the growth
plate (PIXImus Lunar densitometer, GE Healthcare,
Waukesha, WI). Radiographs of the tibiae were taken
prior to sacrifice. At sacrifice, five tumored tibiae fromBMC Cancer 2006, 6:15 http://www.biomedcentral.com/1471-2407/6/15
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each group were embedded in methacrylate for bone his-
tomorphometrical (BHM) analysis.
Bone histomorphometry
BHM analysis was performed on 6-µm longitudinal sec-
tions of calcified tibiae stained with Goldner stain in the
middle of the tibia from five animals per group (Skel-
etech, Inc., Bothell, WA). The percentages of bone volume
and tumor volume in the whole longitudinal section of
tibiae (% BV/TV and % TuV/TV, respectively) were calcu-
lated. Detailed analysis of the trabecular bone, including
determination of trabecular thickness in µm (Tb.Th.),
trabecular number per mm (Tb.N.), trabecular separation
in µm (Tb.Sp.), the ratio of osteoblast surface to bone sur-
face as a percentage, the ratio of osteoclast number to
bone surface as a percentage, osteoid surface to bone sur-
face as a percentage (Os.S/BS) and osteoid thickness
(Os.Th.), was performed in the area adjacent to the
growth plate (0.525–1.225 mm below the growth plate,
site of injection). Statistical analysis of the results was
done using paired and unpaired Student's t tests as appro-
priate.
Effects of docetaxel on subcutaneous tumors
Six-to-eight-week-old male SCID mice were implanted
with LuCaP 23.1 tumor fragments over the right scapular
region. Tumor volume was measured twice weekly and
calculated as L × H × W × 0.5236. After tumors reached
200 mm3 in size, animals were randomized into two
groups. Group 1: animals received intra-peritoneal injec-
tions of PBS every two weeks; Group 2: animals received
intra-peritoneal injections of 20 mg/kg docetaxel (Bristol-
Myers Squibb, Princeton, NJ) every two weeks. Tumor
growth was monitored twice weekly. Animals were sacri-
ficed when the tumors reached ~1000 mm3 or when ani-
mals were becoming compromised.
Results
LuCaP 23.1 causes significant new bone formation with a
pronounced periosteal reaction. Radiographs of ZOL-
treated tibiae show denser bone with a smaller perimeter.
Importantly the tibiae treated with the combination of
ZOL and docetaxel show dense bone and decreases in the
periosteal reaction. Therefore the radiographs demon-
strate a decrease in the overall extensive periosteal bone
formation observed with the LuCaP 23.1 intra-tibial
tumors by both ZOL alone and the combination of ZOL +
docetaxel. Representative examples of the radiographic
appearance of tibiae from control and treated animals are
presented in Figure 1A. Representative examples of the
histological appearance of control and treated tibiae are
shown in Figures 1B–E. The decrease in tumor volume
(red/pink stain) and increase in bone volume (green
stain) upon treatment with ZOL alone (Figure 1C) or the
ZOL + docetaxel combination (Figure 1E) can be clearly
A. Radiographs of treated and untreated LuCaP 23.1 bone  tumors Figure 1
A. Radiographs of treated and untreated LuCaP 23.1 
bone tumors. Extensive new bone formation stimulated by 
LuCaP 23.1 is visible in the control tibiae. Although substan-
tial bone formation is also visible with ZOL and ZOL + 
docetaxel, these tibiae exhibit decreased periosteal activity 
compared to the control and docetaxel-treated tibiae. B.-E. 
Histological appearance of treated and untreated 
LuCaP 23.1 bone tumors. Sections stained with Goldner 
reagent show marrow or tumored areas in pink and bone in 
green. The growth plate is marked with the letter G. The 
ZOL- (C) and ZOL + docetaxel-treated groups (E) exhibit 
substantial increases in bone volume and decreases in tumor 
volume compared to the control (B) and docetaxel-treated 
(D) groups. F. Bone mineral density (BMD) measure-
ments at sacrifice. BMD was measured for the non-
tumored and tumored legs of all four treatment groups. 
BMD was higher in tumored tibiae than in non-tumored tib-
iae, but there were no significant differences among the four 
treatment groups.
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seen in the comparison with the control animal (Figure
1B). The bone in the animals treated with ZOL appears
somewhat more "organized" in the areas adjacent to the
growth plate. This effect may be due to the larger volume
of bone in this area (data not shown).
Effects of osteoblastic CaP xenograft LuCaP 23.1 and ZOL
and docetaxel on bone were further evaluated by measur-
ing BMD. BMD of all tumored tibiae exhibited increased
BMD in comparison to the non-tumored tibia (196–
240% increases, p < 0.0001 for all, Figure 1F). These
increases are due to the stimulation of osteoblastic activity
by LuCaP 23.1 and, in groups 2 and 4, by administration
of ZOL. However, no significant differences in BMD of
tumored tibiae were observed among the four groups. The
systemic effect of ZOL was demonstrated by low but sta-
tistically significant increases in the BMD of non-tumored
tibiae in groups 2 and 4 compared to the normal tibiae of
group 1 (group 1: 0.0496 ± 0.008 g/cm2, group 2: 0.0551
± 0.001 g/cm2 (111%), and group 4: 0.0605 ± 0.001 g/
cm2 (122%), p < 0.002 for both).
We next performed a more detailed analysis of the effects
of the treatments on bone, using bone histomorphome-
try. Groups receiving ZOL (2 and 4) exhibited 58% and
75% increases in bone %BV/TV over the control group (p
= 0.0836 and p = 0.0164). These results are consistent
with the histological appearance of the tibiae (Figures 1B–
E). LuCaP 23.1 and ZOL both caused increases in bone
volume; therefore we cannot determine with certainty the
source of the increases in bone volume – LuCaP 23.1.,
ZOL alone, or the reduction in volume of the tumors com-
bined with the anti-resorptive properties of ZOL. In our
study the %BV/TV did not correlate with BMD values. This
discordance may be due to potential effects of the treat-
ments on mineral deposition or the methodology used.
Trabecular numbers and Tb.Sp. were similar in all 4
groups, with a trend to increased Tb.Th in group 2, which
received ZOL alone (group 2: p = 0.0705). Os.S/BS was
decreased in ZOL-treated animals by 35–45%, but these
differences were not statistically significant, and no differ-
ences were detected in Os.Th. between the groups. ZOL
administration resulted in decreased numbers of osteo-
clasts (Table 1, group 1 vs. group 2: p = 0.0092; group 1 vs.
group 4: p = 0.0030). Osteoblast perimeter was not signif-
icantly altered by any of the treatments.
An important goal of our study was to determine the
effects of ZOL and docetaxel and their combination on
tumor growth. Tumor growth during the course of the
treatments was monitored by PSA serum levels. Adminis-
tration of ZOL and docetaxel alone did not decrease
serum PSA levels in comparison to the control group (Fig-
ure 2B). However, the combination of these two agents
decreased serum PSA levels to approximately 44% of that
of the control animals (p < 0.05). We measured tumor
volume at the time of sacrifice using BHM analysis.
Administration of ZOL alone significantly decreased
tumor volume in comparison to the control group (100.0
± 8.4% vs. 57.7 ± 12.8%, p = 0.027). Administration of
docetaxel alone at the dose used was not effective in
tumor inhibition (92.4 ± 16.2%, p = 0.689). Importantly
the combination of ZOL and docetaxel decreased tumor
growth in comparison to control animals to 36.4 ± 5.00%,
p = 0.0002. Administration of docetaxel in combination
with ZOL resulted in decreased tumor volume in compar-
ison to animals receiving ZOL alone; however, these
results did not reach significance (63.0 ± 8.6%, p = 0.111).
We have also evaluated the effects of 20 mg/kg docetaxel
on growth of subcutaneous LuCaP 23.1 tumors. This dose
was effective in inhibiting growth of subcutaneous LuCaP
23.1 (Figure 3A). Serum PSA levels were also significantly
decreased in animals who received docetaxel treatment
(Figure 3B). Decreases in serum PSA levels were in con-
cordance with tumor volume.
Discussion
CaP is an extremely heterogeneous disease, and to date
treatment strategies with single agents have failed to cure
advanced prostate cancer. New multimodality therapeutic
combinations that target different pathways and produce
pronounced and sustained clinical activity without severe
toxicity are now considered the next frontier in treating
Table 1: Results of histomorphometrical analysis of effects of the treatments on LuCaP 23.1 and bone
BV/TV 
(%)
TUV/TV 
(%)
TB.TH. 
(µM)
TB. N. 
(MM-1)
TB.SP. 
(µM)
OS.S./BS 
(%)
OS.TH. 
(µM)
OB.PM./BPM. 
(%)
N.OC./BS 
(%)
Control 23.09 ± 9.34 30.62 ± 5.75 94.89 ± 31.75 6.06 ± 1.41 76.87 ± 20.90 7.24 ± 1.82 4.57 ± 0.29 15.97 ± 5.08 1.91 ± 0.35
ZOL 36.51 ± 7.86 17.68 ± 6.79a 145.7 ± 31.64 5.08 ± 0.53 52.29 ± 13.51 3.96 ± 1.87 5.27 ± 0.45 8.46 ± 1.42a 0.83 ± 0.46a
DOC 29.46 ± 8.56 28.29 ± 11.18 81.53 ± 20.45 5.61 ± 0.90 100.6 ± 24.88 6.73 ± 1.84 5.21 ± 0.36 14.17 ± 4.36 1.19 ± 0.61
ZOL + DOC 40.38 ± 8.73a 11.13 ± 3.41a,b 118.5 ± 25.56 5.59 ± 0.51 61.48 ± 21.83 4.77 ± 1.01 4.98 ± 0.40 11.92 ± 5.90 0.77 ± 0.42a
Tumored tibiae were harvested after seven weeks of treatment and embedded in methacrylate. Analysis was performed on Goldner-stained 
longitudinal sections of tibiae (n = 5 per group).
Results are presented as a mean ± SD.
a p < 0.5 vs. control group
b p = 0.11 group 2 vs. group 4BMC Cancer 2006, 6:15 http://www.biomedcentral.com/1471-2407/6/15
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advanced CaP. However, as expected, not all combina-
tions will be superior to monotherapies; e.g., combina-
tions of ZOL with Imatib mesylate (Gleevec) [46] or high
doses of calcitriol and dexamethasone [27] are reported to
have no beneficial effects beyond those of monotherapy.
ZOL has recently emerged as an effective treatment for
inhibition of both normal and pathologic bone resorp-
tion, and this has had a major impact on the treatment of
metastases to the bone. In advanced CaP, ZOL has been
shown to significantly reduce bone pain and the incidence
of skeletal complications [47]. We have shown previously
that ZOL inhibits growth of osteoblastic LuCaP 23.1 in
the bone environment [15] and our new data show that
lower amounts of ZOL (0.1 mg/kg) are also effective in
suppression of LuCaP 23.1 growth in bone. In an earlier
article we reported lowering of PSA levels as well as tumor
volume by ZOL [15]. The difference may be due to the
lower dosage of ZOL used in the current study. Docetaxel-
induced alterations in serum PSA levels followed tumor
volume in animals harboring subcutaneous LuCaP 23.1,
whereas ZOL treatment of LuCaP 23.1 in bone decreased
tumor volume, but changes in serum PSA were not signif-
icant. We hypothesize that PSA may not reflect changes in
the response of CaP bone metastases to ZOL treatment,
and that regulation of tumor growth and of PSA expres-
sion are affected by different signaling pathways and to
different extents in the bone environment.
Although the main action of ZOL is inhibition of osteo-
clastic bone resorption [19], there is some evidence sug-
gesting direct anti-tumor effects of ZOL as well as a
possible synergism with taxanes [9, 17, 48]. Taxanes have
been shown to be effective against osteolytic experimental
CaP metastases [49, 50] and docetaxel has recently been
approved as a standard chemotherapy for advanced pros-
tate cancer. In the present study, 20 mg/kg docetaxel
administered every two weeks significantly inhibited the
growth of subcutaneous LuCaP 23.1. However, the effec-
tiveness of docetaxel as a single drug against growth of
LuCaP 23.1 in the bone was insignificant. We speculate
that the bioavailability of docetaxel may be reduced in the
osteoblastic environment.
In the present study, administration of ZOL apparently
had the effect of sensitizing the target cells to the effects of
docetaxel. In fact in the presence of ZOL, the additional
effect of docetaxel (~37% reduction in growth) was
almost as great as that seen with ZOL compared with the
control group (~42% reduction), although it should be
noted that the comparison between ZOL and the ZOL/
docetaxel combination failed to reach statistical signifi-
cance because of modestly higher scatter within the ZOL-
only group. Similar results were recently published by
Kim et al. [50], who reported that ZOL and paclitaxel each
A. Effects of ZOL and docetaxel treatments on bone volume Figure 2
A. Effects of ZOL and docetaxel treatments on bone 
volume. Bone volume as a percentage of the total volume 
was determined by bone histomorphometrical analysis. The 
ZOL + docetaxel treatment significantly increased bone vol-
ume compared to that of the control group (p = 0.0164, *). 
%BV/TV of the ZOL group was increased in comparison to 
the control group but the changes did not reach significance 
(p = 0.0839). B. Effects of ZOL and docetaxel treat-
ments on serum PSA levels. Blood was drawn weekly 
from each treatment group, control (■ ), ZOL (● ), 
Docetaxel (▼ ), or ZOL + docetaxel (❍ ), and analyzed for 
PSA levels (ng/ml). The combination of ZOL + docetaxel 
decreased PSA levels significantly compared to those in the 
control animals. C. Effects of ZOL and docetaxel treat-
ments on tumor volume. Tumor volume as a percentage 
of the total volume was determined by bone histomorpho-
metrical analysis for the four treatment groups. The ZOL 
and ZOL + docetaxel treatments decreased tumor volume 
significantly (p = 0.027, 0.0002, respectively *) compared to 
that of the control group. The combination of ZOL and 
docetaxel resulted in decreased tumor volume in compari-
son to animals receiving ZOL alone; however, these results 
did not reach significance (p = 0.111).
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inhibited tumor growth in models of experimental osteo-
lytic bone metastases of CaP, and the inhibition was even
more pronounced with the combination. Studies employ-
ing combinations of agents in androgen-independent pre-
clinical models are also needed to extend these
observations to a setting more similar to advanced CaP
patients.
Conclusion
Our data show that the combination of ZOL and
docetaxel is effective in inhibiting growth of osteoblastic
metastases of prostate cancer. Because of the toxicity of
chemotherapeutic agents such as docetaxel, it is important
to insure that they are effective against disease as adminis-
tered. Our data indicate that the single-agent effectiveness
of docetaxel in the osteoblastic CaP environment may be
limited, but ZOL may sensitize the target cells to the
effects of docetaxel. These data support clinical evaluation
of this combination in CaP patients.
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